Cingulate therapeutics filing

Author: xtox

August undefined, 2024

WebSep 9, 2024 · Cingulate Inc. S-1 Filing information. Filed on 9 September 2024 SEC Edgar 000149315221022284 Exhibits & attachments & exports. ... Top menu > File > Make a copy... Copy & paste the following URL into the D2 cell: Do you need help with the setup? Let us know at [email protected]. Close.

CING Stock Forecast, Price & News (Cingulate) - MarketBeat

WebJul 11, 2024 · About Cingulate Therapeutics ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ... WebCingulate Therapeutics is a Biotechnology, Pharmaceuticals, and Pharmaceutical Manufacturing company located in Morristown, New Jersey with $2.00 Million in revenue and 14 employees. Find top employees, contact details and business statistics at RocketReach. ... (28 currently) – along with the filing of multiple provisional applications ... shudder yearly

Cingulate Therapeutics Initiates First Human Clinical Trial - PR …

WebUncategorized (1) Contracts. Master Services Agreement between Cingulate Therapeutics LLC and Societal CDMO, Inc., dated October 24, 2024 (Filed With SEC on October 25, 2024) Promissory Note, dated August 9, 2024, between Cingulate Therapeutics, LLC and Werth Family Investment Associates LLC (Filed With SEC on August 11, 2024) … WebMar 31, 2024 · The transplantation of neural progenitors into a host brain represents a useful tool to evaluate the involvement of cell-autonomous processes and host local cues in the regulation of neuronal differentiation during the development of the mammalian brain. Human brain development starts at the embryonic stages, in utero, with unique … WebCingulate General Information. Description. Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery … the other nra

CING Stock Price Cingulate Inc. Stock Quote (U.S.: Nasdaq ...

Cingulate Therapeutics LLC - Company Profile and News

WebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva; Cingulate Inc. Reports First Quarter 2024 Results … WebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. … 10 Mar 2024 Cingulate Inc. Reports Fourth Quarter and Full Year 2024 Financial … Pipeline Overview. Cingulate® completed a proof-of-concept trial in human subjects … Cingulate Inc. 1901 W 47th Place Kansas City, KS 66205 (913) 942-2300 … Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and … About Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage … Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member … The Investor Relations website contains information about Cingulate Inc's … the other obsWeb8 rows · Jun 29, 2024 · Cingulate Therapeutics - Most recent fund raising on June 29, 2024 raised $7,000,000 in Equity and Debt shudder xbox one

"WebCINGULATE THERAPEUTICS LLC: TEXAS FOREIGN LIMITED-LIABILITY COMPANY (LLC) WRITE REVIEW: Address: 1901 W. 47th Place, Ste 310 Kansas City, KS 66205: Registered Agent: C T Corporation System: Filing Date: June 06, 2024: File Number: 0803337838: Contact Us About The Company Profile For Cingulate Therapeutics LLC " - Cingulate therapeutics filing

Cingulate therapeutics filing

WebJul 3, 2024 · Cingulate Therapeutics - ‘D/A’ on 7/3/19 - Notice of an Exempt Offering of Securities - Seq. 1 - Amendment to Notice of an Exempt Offering of Securities -- primary_doc.xml/7.8 - Accession Number 0001593151-19-000001 - Filing - SEC WebApr 6, 2024 · Alterity Therapeutics NASDAQ:ATHE; View All Competitors. Insiders & Institutions. HighTower Advisors LLC Bought 34,425 shares on 2/9/2024 Ownership: …

Did you know?

WebCingulate Therapeutics is based out of Morristown. The firm last filed a Form D notice of exempt offering of securities on 2024-06-29. The notice included securities offered of … WebSep 9, 2024 · Cingulate Inc. S-1 Filing information. Filed on 9 September 2024 SEC Edgar 000149315221022284 Exhibits & attachments & exports. ... Top menu > File > Make a …

WebApr 2, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ... WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 6 SOUTH STREET: SUITE 203: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; MORRISTOWN: NEW …

WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 1901 W. 47th Place: Third Floor: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; Kansas City: … WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate …

WebSep 24, 2014 · Somerset, N.J. – September 24, 2014 — Catalent Pharma Solutions has reached an exclusive development and licensing agreement with privately held biopharmaceutical company, Cingulate Therapeutics (CTx), to support the development of a series of new prescription pharmaceutical products for the treatment of Attention …

WebJul 10, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both products in the first quarter of 2024 and will pursue approval via the accelerated 505 (b)(2) regulatory pathway. ... the other od-3 modWebJun 29, 2024 · The most recently filed 13Fs shudder xfinityWebApr 11, 2024 · On April 04, 2024, Cingulate Inc. (NASDAQ: CING) announced it had completed the first cohort of its Phase 3 adult onset and duration trial of its lead candidate, CTx-1301 (dexmethylphenidate), for attention deficit/hyperactivity disorder (ADHD). The Phase 3 CTx-1301-022 study (NCT05631626) assesses the onset and duration of CTx … shudder year priceWebMay 31, 2024 · Cingulate anticipates filing INDs for CTX-1301 and CTX-1302 via the accelerated 505 (b)(2) regulatory pathway. The company has offices in Kansas City, KS and Morristown, NJ. For more information ... shudder yearly costWebSep 14, 2024 · Cingulate, Inc. ( NASDAQ: CING) is a clinical-stage biopharmaceutical company with a proprietary Precision Timed Release (PTR) drug delivery platform … the other officeWebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva; Cingulate Inc. Reports First Quarter 2024 Results and Provides Clinical and Business Update Announcement of First Subject Dosing for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ … the other office baguio cityWebFunding. Cingulate Therapeutics has raised a total of $7.6M in funding over 3 rounds. Their latest funding was raised on Jul 11, 2024 from a Venture - Series Unknown round. Cingulate Therapeutics is registered under the ticker NASDAQ:CING . Their stock opened with $6.00 in its Dec 8, 2024 IPO. shudder yearly price